What has apparently triggered this systematic review and metaanalysis is a paper published in JAMA in 2009 (ref 11), the authors of which combined the extended post-trial follow-up time results of two Norwegian randomized controlled clinical trials (RCTs) (ref 12 and 13) and reported an increased incidence of cancer among patients taking folic acid to reduce homocysteine levels for secondary prevention of cardiovascular events.
considered). However, increased cancer risk was found in studies with a dose from 0.4 to 1 mg per day and not in studies in which folic acid doses exceeded 1 mg per day, thus raising concerns about whether dose-response patterns were adequately captured across the range of exposures.
Answer:
In our sensitivity analyses of the RCTs, the studies with dose interval 0.4-1 mg/day were associated with a higher risk of cancer development than studies with doses above 1 mg/day, with relative risks of 1.21 (1.06-1.38) and 1.03 (0.96-1.11) respectively. Our systematic search had no dose limitation and thus allowed us to search for all dose ranges, although our eligibility criteria specified doses ≥ 0.4 mg/day. We identified no RCTs, but eleven observational studies with doses below 0.4 mg/day reporting cancer incidence, thus allowing us post hoc to evaluate a possible dose-response pattern of observational studies including doses below 0.4 mg/day. Six of these studies were already included in our review, as they contained also groups with daily intakes ≥ 0.4 mg [1] [2] [3] [4] [5] [6] , and five were excluded from our main analyses due to daily dose of folic acid below 0.4 mg [7] [8] [9] [10] [11] . No increased risk was found in the meta-analyses of doses below 0.4 mg/day, with a pooled relative risk of 1.07; 95% CI 0.92-1.26 for the cohort studies [2] [3] [4] [5] [6] [7] [8] [9] and 1.17 (0.95% CI 0.58-2.33) for the case-control studies 1;8 . Hence, our analyses did not support any dose-response pattern between folic acid dose and cancer incidence.
As you see we take care of this dose-response question in the revised Discussion (page 17-18). This is because we want to keep to our protocol that had folic acid supplement ≥0.4 mg/day as an eligibility criterion.
A statistically significant increase in incidence was found essentially with respect to prostate cancer, for which no significant increase was found with respect to mortality. However, excess incidence was evident only after 60 months of follow-up, that is to say most likely during the post-trial period, that is, a period which is not "bias-immune" (e.g. PSA testing can bypass the issue of latency).
Answer: Our meta-analysis of prostate cancer incidence consists of six RCTs. The studies had a followup time from 52-84 months. All the studies had the same treatment time as follow up-time, except In the first set of lines, low folate intake is reported to be protective against early carcinogenesis. In the second set of lines, lower folic acid intakes are associated with higher risk of cancer development.
Answer: Agree, we have corrected this in the revised manuscript. Negative findings are downplayed throughout the manuscript. Even more disappointingly perhaps is the underreporting of results from observational studies. This is of concern because such studies provide valuable information, as they are not confined to strict RCTs criteria, and complement randomised studies.
Answer: We agree. We have rephrased our interpretation of the data throughout the manuscript, changing moderate to borderline and including the results from the observational studies in a much more detailed manner, as well as showing negative results more clearly.
It should be further stressed that an important limitation of the meta-analysis is the lack of information on dietary patterns in the studied populations.
Significant differences in folate content among different food types (and food processing) might have influenced the reported findings.
Answer: Yes we agree to this possibility, but nevertheless this lacking information in the clinical studies might be randomly distributed across the study populations.
A better justification of why studies on food fortification were not considered is needed in both introduction and discussion. The results of RCTs/observational studies in Canada and USA are likely to be influenced by the introduction of mandatory food fortification, particularly when this occurred during the conduct of such studies. Cancer incidence and mortality should be compared between those studies in countries where mandatory folate fortification was implemented from those studies where folate fortification was not introduced.
Answer: Two of the RCTs 12;13 were done in USA after introduction of fortification. Sensitivity analysis of those two compared to the studies performed in the countries without fortification, showed no significant difference between the groups (Figure 2c) ; i.e populations with fortification did not show increased cancer risk with folate supplements compared to studies performed in countries before fortification/ countries without fortification.
SPECIFIC COMMENTS
Abstract_results_a: 95% CI cancer incidence data for 1-2 relevant cancer types other than prostate (e.g. colon and breast) are required. Negative data, in addition to positive associations, should be reported.
Answer: This has been performed in the revised manuscript.
Abstract_results_b: for the same reason 95% CI total cancer mortality data should be reported.
Abstract_results_c: once again, 95% CI data for cancer risk in observational studies must be reported.
Answer: This has been reported in the results chapter.
Abstract_conclusions_a: 'FA might moderately increase total cancer incidence' is clearly an overstatement. With an RR of 1.07 and CI of 1.00-1.14 the risk is very mild at best. Also, the conclusions should reflect the findings (negative) from observational studies.
Answer: we have rephrased and added findings from observational studies (please see our answer under General Comments above).
Abstract_conclusions_b: the conclusions on prostate cancer should also reflect the negative findings of observational studies.
Answer: There was no observational studies reporting on prostate cancer in our included studies. What this study adds: once again, the first bullet point ('moderately increase') is an overstatement.
Answer: We agree and this has been updated in the revised version.
Introduction_a: data on prevalence of folate deficiency would be useful.
Answer: We have rephrased this paragraph.
Results_a: a full list of observational studies considered should also be provided in Table format Premenopausal breast cancer risk and intake of vegetables, fruits, and related nutrients. J Natl Cancer Inst 1996; 88(6):340-348.
